BeiGene held its 2024 Annual General Meeting on June 5, with shareholders approving several significant resolutions. The Third Amended and Restated 2016 Share Option and Incentive Plan was approved, increasing available shares by 92,820,000. The Fourth Amended and Restated 2018 Employee Share Purchase Plan was also approved, adding 5,070,000 shares.Shareholders re-elected four Class II directors: Dr. Olivier Brandicourt, Mr. Donald W. Glazer, Mr. Michael Goller, and Dr. Corazon Sanders. Ernst & Young was ratified as the company's independent auditor for FY2024. The Board received authorization to issue up to 20% new shares and repurchase up to 10% of outstanding shares (excluding RMB shares).Compensation plans for executives and independent directors were approved, including RSUs and PSUs for CEO John V. Oyler and RSUs for other key personnel. Shareholders also voted for annual advisory votes on executive compensation. The meeting had a quorum with approximately 77.53% of outstanding shares represented.

BeiGene held its 2024 Annual General Meeting on June 5, with shareholders approving several significant resolutions. The Third Amended and Restated 2016 Share Option and Incentive Plan was approved, increasing available shares by 92,820,000. The Fourth Amended and Restated 2018 Employee Share Purchase Plan was also approved, adding 5,070,000 shares.Shareholders re-elected four Class II directors: Dr. Olivier Brandicourt, Mr. Donald W. Glazer, Mr. Michael Goller, and Dr. Corazon Sanders. Ernst & Young was ratified as the company's independent auditor for FY2024. The Board received authorization to issue up to 20% new shares and repurchase up to 10% of outstanding shares (excluding RMB shares).Compensation plans for executives and independent directors were approved, including RSUs and PSUs for CEO John V. Oyler and RSUs for other key personnel. Shareholders also voted for annual advisory votes on executive compensation. The meeting had a quorum with approximately 77.53% of outstanding shares represented.